8-K: Lisata Reports Q3 2025 Results, Extends Cash Runway

Lisata Therapeutics announced positive clinical data from multiple certepetide trials, strategic partnerships, and extended its cash runway into Q1 2027, alongside a decrease in operating expenses for Q3 2025.

Summary

• Positive data was reported from several clinical studies involving certepetide, including the ASCEND, iLSTA, and CENDIFOX trials.
• A strategic alliance was formed with GATC Health to utilize their Multiomics Advanced Technology artificial intelligence drug discovery platform.
• A global license agreement was entered into with Catalent for the use of certepetide as part of their SMARTag Antibody-Drug Conjugate Technology Platform.
• Cash and cash equivalents totaled approximately $19.0 million as of September 30, 2025.
• The projected cash runway has been extended into the first quarter of 2027, with no debt.
• Operating expenses for the three months ended September 30, 2025, decreased by $0.9 million, or 17.3%, to $4.4 million compared to $5.3 million for the same period in 2024.
• Net loss for the three months ended September 30, 2025, was $4.2 million, compared to $4.9 million for the same period in 2024.

Sentiment

Score: 8

Explanation: The company reported positive clinical data across multiple trials for its lead candidate, certepetide, demonstrating its potential in various solid tumors and in combination with different anti-cancer agents. Strategic partnerships with Catalent and GATC Health validate the platform technology and open new avenues for development and revenue. Furthermore, effective expense management has extended the cash runway into Q1 2027, providing a longer operational horizon without immediate financing needs. While the company still reports a net loss, this is expected for a clinical-stage pharmaceutical company, and the reduction in loss is a positive sign.

Positives

• Preliminary data from ASCEND Cohort A showed a positive trend in overall survival, including four complete responses in the certepetide-treated group compared to none in the placebo group for metastatic pancreatic ductal adenocarcinoma (mPDAC).
• Preliminary data from ASCEND Cohort B demonstrated a positive signal in progression-free survival and objective response rate, indicating a clinically meaningful treatment effect and attractive safety profile.
• Pooled data from ASCEND Cohorts A and B corroborated previous findings and indicated no increase in adverse events in the certepetide-treated groups beyond those experienced in the standard-of-care (SoC) alone groups.
• Enrollment in the BOLSTER trial for first-line cholangiocarcinoma (CCA) was completed nearly six months ahead of plan, accelerating anticipated topline data readout to Q4 2025.
• The CENDIFOX trial showed that the combination of certepetide with FOLFIRINOX was safe and feasible, resulting in a 50% R0 resection rate and a 70% pathologic partial response in the PDAC cohort, along with a 60% two-year overall survival rate.
• CENDIFOX data suggests the combination therapy appears to transform tumors from 'immune-cold' to 'immune-hot' by enhancing immune cell infiltration.
• Interim analysis results from the iLSTA trial showed compelling new corroborative data for certepetide, demonstrating its potential to enhance immunotherapy effectiveness.
• Lisata and Catalent entered into a nonexclusive license agreement, granting Catalent global rights to evaluate certepetide for use as SMARTag payloads across multiple Antibody-Drug Conjugates (ADCs).
• Preclinical data from Catalent's study evaluating certepetide as non-cytotoxic SMARTag ADC payloads showed improved ADC efficacy and broadened distribution of the cytotoxic payload within the tumor.
• Lisata entered into a strategic alliance with GATC Health to exploit their AI-powered Multiomics Advanced Technology platform for drug discovery and development.
• The company's cash runway has been extended into the first quarter of 2027 with no debt, reflecting continued vigilance in managing expenses.
• Operating expenses decreased by 17.3% in Q3 2025 compared to Q3 2024, and net loss decreased by $0.7 million.
• Certepetide has been awarded Fast Track designation (U.S.) and Orphan Drug Designation for pancreatic cancer (U.S. and E.U.), glioma, osteosarcoma, and cholangiocarcinoma (U.S.), as well as Rare Pediatric Disease Designation for osteosarcoma (U.S.).
• Certepetide possesses a strong Intellectual Property portfolio with composition of matter patent through March 2040, with subsequent opportunity for patent term extension.
• Requisite clinical development steps, including an FDA end-of-Phase 2 meeting, have been completed in preparation for a global Phase 3 trial in mPDAC, with the study design agreed upon with the FDA.

Negatives

• The company reported a net loss of $4.2 million for the three months ended September 30, 2025.
• Cash, cash equivalents, and marketable securities decreased from $31.245 million at December 31, 2024, to $18.998 million at September 30, 2025.
• ASCEND Cohort A, powered for 6-month PFS, showed no statistically significant improvement with certepetide in progression-free survival.

Risks

• Results observed from preliminary data are not necessarily indicative of final results, and one or more of the clinical outcomes may materially change following more comprehensive reviews of the data and as more patient data becomes available.
• There is a risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations.
• Product candidates that appeared promising in early research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials.
• The safety and efficacy of Lisata's product candidates are subject to ongoing evaluation.
• Decisions of regulatory authorities and the timing thereof, as well as the duration and impact of regulatory delays in clinical programs, could affect development timelines.
• The company's ability to finance its operations and the likelihood and timing of the receipt of future milestone and licensing fees are uncertain.
• The future success of Lisata's scientific studies and its ability to successfully develop and commercialize drug candidates are not guaranteed.
• Predicting the time and cost of development of Lisata's product candidates is difficult.
• Rapid technological change in Lisata's markets could impact its competitive position.
• The ability of Lisata to protect its intellectual property rights is crucial.
• Legislative, regulatory, political, and economic developments could affect the company's operations.
• For investigator-initiated trials, Lisata has limited control, and thus, timelines and expectations may be subject to change.
• The FDA's Priority Review Voucher program, which provides significant value, expires in September 2026 and may not be renewed.

Future Outlook

Lisata Therapeutics anticipates a steady flow of additional data through the remainder of 2025 and into 2026 from its ongoing clinical trials. The company projects that its available cash will fund current operations into the first quarter of 2027. Preparations for a global Phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC) are underway, with the study design agreed upon with the FDA, including the potential for multiple dosing arms.

Management Comments

• "Once again, the recent quarter saw the reporting of positive data from a number of clinical studies involving certepetide, including from the ASCEND, iLSTA, and CENDIFOX trials."
• "Importantly, we also announced a strategic alliance with GATC Health to use their Multiomics Advanced Technology artificial intelligence drug discovery platform to identify product candidates for development, as well as a global license agreement in which Catalent gained access to certepetide for use across various Antibody-Drug Conjugates."
• "Overall, it was a productive and positive quarter marked by our continued vigilance in managing expenses."
• "As a result, we now project that our available cash will fund current operations into the first quarter of 2027."
• "We anticipate a steady flow of additional data through the remainder of 2025 and into 2026."

Industry Context

The announcement highlights Lisata's commitment to addressing the significant unmet medical need in advanced solid tumors, particularly pancreatic cancer, where current treatments are often suboptimal and immunotherapies face challenges. Certepetide's unique mechanism of action, which enhances drug penetration into tumors and modifies the tumor microenvironment, positions it as a valuable adjuvant to existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies, and Antibody-Drug Conjugates (ADCs). The strategic partnerships with Catalent and GATC Health align with broader industry trends focusing on targeted drug delivery and leveraging artificial intelligence for accelerated drug discovery and development, indicating a forward-looking approach within the competitive oncology landscape.

Comparison to Industry Standards

• Certepetide plus standard-of-care (SoC) chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC) has demonstrated improved overall survival akin to the recently FDA-approved NALIRIFOX triplet therapy.
• In the CEND1-001 Australia Phase 1b/2a trial, SoC + certepetide showed a median overall survival (mOS) of 13.2 months, representing a 55% improvement compared to the 8.5 months mOS reported for SoC (gemcitabine + nab-paclitaxel) in the Von Hoff 2013 Phase 3 registration study.
• In the CEND1-201 China Phase 1b/2a trial, SoC + certepetide showed an mOS of 11.1 months, representing a 31% improvement compared to the 8.5 months mOS from the Von Hoff 2013 Phase 3 study.
• Catalent's preclinical data demonstrated that SMARTag ADCs incorporating MMAE+iRGD enabled equal efficacy at a lower MMAE DAR (Drug-to-Antibody Ratio) and a lower dosage compared to Datopotamab vedotin, suggesting enhanced efficiency in payload delivery and tumor response.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical data, strategic partnerships, extended cash runway, and progress towards Phase 3. Reduced operating expenses and net loss are also favorable.
• Patients: Potential for improved treatment options for advanced solid tumors, especially pancreatic cancer, glioblastoma, and cholangiocarcinoma, through certepetide's ability to enhance drug delivery and modify the tumor microenvironment.
• Employees: Continued stability and focus on drug development with an extended cash runway.
• Partners (Catalent, GATC Health, Qilu, AGITG, WARPNINE, KUCC, Tartu University): Strengthened collaborations and potential for shared success in drug development and commercialization.
• Regulatory Authorities: Ongoing engagement with FDA for Fast Track, Orphan Drug, and Rare Pediatric Disease Designations, and agreement on Phase 3 study design.

Next Steps

• Anticipate a steady flow of additional data through the remainder of 2025 and into 2026 from ongoing clinical trials.
• Final data and key findings from both cohorts of the ASCEND study are anticipated for the first quarter of 2026.
• Additional CENDIFOX data are expected in the coming months under the auspices of the investigator.
• Final data from the iLSTA study are anticipated in the first quarter of 2026.
• Qilu Pharmaceutical's Phase 2 trial data are expected in 2026.
• Enrollment completion for the GBM Phase 2a study is expected in 2026.
• Topline data readout for BOLSTER first-line CCA is anticipated in the fourth quarter of 2025.
• Preparations for a global Phase 3 study in mPDAC are underway, with the design agreed upon with the FDA.
• Lisata will hold a live conference call on November 6, 2025, at 4:30 p.m. Eastern Time to discuss financial results, provide a business update, and answer questions.

Key Dates

Recommendation

The filing presents a highly positive outlook for Lisata Therapeutics. The consistent reporting of positive clinical data across multiple trials (ASCEND, CENDIFOX, iLSTA) for certepetide, particularly in difficult-to-treat cancers like mPDAC, significantly de-risks the asset and strengthens its commercial potential. The strategic partnerships with industry leaders like Catalent (ADCs) and GATC Health (AI drug discovery) not only validate Lisata's CendR Platform technology but also provide additional revenue streams and expand certepetide's applicability. Critically, the extension of the cash runway into Q1 2027, coupled with reduced operating expenses and net loss, demonstrates strong financial management and provides a clear path forward for advancing its clinical programs, including the agreed-upon global Phase 3 for mPDAC, without immediate dilution concerns. The multiple regulatory designations (Fast Track, Orphan Drug, Rare Pediatric Disease) further enhance the value proposition. These factors collectively suggest a strong growth trajectory and significant upside potential for investors.

Keywords

Lisata Therapeutics, LSTA, certepetide, pancreatic cancer, mPDAC, solid tumors, oncology, clinical trials, Antibody-Drug Conjugate, ADC, Catalent, GATC Health, AI drug discovery, tumor microenvironment, immunotherapy, Q3 2025 financial results, biopharmaceutical, drug development, glioblastoma, cholangiocarcinoma